2022
DOI: 10.3389/fgene.2022.1057293
|View full text |Cite
|
Sign up to set email alerts
|

Increased diagnostic yield in a cohort of hearing loss families using a comprehensive stepwise strategy of molecular testing

Abstract: Hearing loss is one of the most common sensory disorders in humans. This study proposes a stepwise strategy of deafness gene detection using multiplex PCR combined with high-throughput sequencing, Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and whole-exome sequencing (WES) to explore its application in molecular diagnosis of hearing loss families. A total of 152 families with hearing loss were included in this study, the highest overall diagnosis rate was 73% (111/152). The diag… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

2
2

Authors

Journals

citations
Cited by 4 publications
(7 citation statements)
references
References 64 publications
0
7
0
Order By: Relevance
“…This set comprises a total of 1450 hearing loss probands mainly from Henan Province, China, and it includes syndromic and nonsyndromic hearing loss. Most of the cohort was first tested by a lab-developed multiplex PCR kit covering the total coding sequencing of GJB2 , SLC26A4 , and MT-RNR1 [described in a previous study (Zeng et al 2022b )], as these are the most common causative genes in this population. If negative, exome sequencing was performed [the so-called step-wise approach as described previously (Zeng et al 2022b )].…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…This set comprises a total of 1450 hearing loss probands mainly from Henan Province, China, and it includes syndromic and nonsyndromic hearing loss. Most of the cohort was first tested by a lab-developed multiplex PCR kit covering the total coding sequencing of GJB2 , SLC26A4 , and MT-RNR1 [described in a previous study (Zeng et al 2022b )], as these are the most common causative genes in this population. If negative, exome sequencing was performed [the so-called step-wise approach as described previously (Zeng et al 2022b )].…”
Section: Methodsmentioning
confidence: 99%
“…Most of the cohort was first tested by a lab-developed multiplex PCR kit covering the total coding sequencing of GJB2 , SLC26A4 , and MT-RNR1 [described in a previous study (Zeng et al 2022b )], as these are the most common causative genes in this population. If negative, exome sequencing was performed [the so-called step-wise approach as described previously (Zeng et al 2022b )]. A fraction of patients chose exome sequencing as the first-tier test, while others with negative multiplex PCR were not tested by exome sequencing if DNA from both parents was not available.…”
Section: Methodsmentioning
confidence: 99%
“…This set is comprised of a total of 1450 hearing loss probands and it includes syndromic and non-syndromic hearing loss. Most of the cohort was first tested by a lab-developed multiplex PCR kit covering the total coding sequencing of GJB2 , SLC26A4 , and MT-RNR1 (described in a previous study (Zeng et al 2022b)), as these are the most common causative genes in this population. If negative, exome sequencing was performed (the so-called step-wise approach as described previously (Zeng et al 2022b)).…”
Section: Methodsmentioning
confidence: 99%
“…Most of the cohort was first tested by a lab-developed multiplex PCR kit covering the total coding sequencing of GJB2 , SLC26A4 , and MT-RNR1 (described in a previous study (Zeng et al 2022b)), as these are the most common causative genes in this population. If negative, exome sequencing was performed (the so-called step-wise approach as described previously (Zeng et al 2022b)). A fraction of patients chose exome sequencing as the first-tier test, while others with negative multiplex PCR were not tested by exome sequencing if DNA from both parents was not available.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation